Louvain-la-Neuve, Belgium, 23 May 2024 - IBA , the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2024. Group Overview .
Louvain-La-Neuve, Belgium, 2 May 2024 - IBA , the world leader in particle accelerator technology, today announces that it has signed a contract with the Connecticut Proton Therapy Center, a.
Contract with IAEA demonstrates Cyclone® KEY’s accessibility for low- and middle-income countries Louvain-la-Neuve, Belgium, February 29, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that it has signed a contract for a Cyclone® KEY cyclotron with the International Atomic Energy Agency (IAEA). This cyclotron will be installed at the Univers
Highly complementary acquisition continues IBA’s expansion strategy to lead the Radiotherapy, Medical Imaging Dosimetry and Quality Assurance markets globally Louvain-la-Neuve, Belgium, February 9, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, announced today it has signed an agreement to acquire all the assets of Radcal Corporation, a leader in diagnostic X-ra